Resources

  • Statement

    Life Science Venture Capital Responds to President Biden’s FY24 Budget 
    03.09.2023

    Today, March 9th, 2023, President Biden released his Fiscal Year (FY) 2024 proposed budget and recommendations. Notably, one proposal indicates that the President seeks to expand price controls established in the Inflation Reduction Act of 2022.

  • Statement

    Life Science Venture Capital Responds to President Biden’s State of the Union 
    02.08.2023

    We must bolster the scientific biopharmaceutical ecosystem, not abandon it. 

  • Video

    The Inflation Reduction Act- Explained by Incubate
    12.15.2022

    Incubate breaks down the Inflation Reduction Act, diving into implications and potential impacts on life science development. Keep up with...

  • Video

    The Inflation Reduction Act: Implications for Biopharma Companies and Patients
    09.23.2022

    See our webinar, featuring DLA Piper, on the Inflation Reduction Act healthcare provisions.

  • Statement

    Incubate Statement on Amendment 5284 of the Inflation Reduction Act
    08.06.2022

    Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:

  • Article

    US Government Poised for Long-Awaited Powers on Drug Pricing
    08.06.2022

    Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated

  • Article

    HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
    08.04.2022

    Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.

  • Article

    Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
    08.03.2022

    Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.

  • Article

    Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
    08.03.2022

    A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.

  • Video

    Incubate Investor Panel on the Senate’s Inflation Reduction Act of 2022
    08.03.2022

    Members of Incubate's network, Peter Kolchinsky, PhD, Managing Partner at RA Capital Management; JF Formela, MD, Partner at Atlas Venture; Guarav Gupta, MD, MS - Founder and Managing Partner, Ascendant BioCapital; and Duane Schulthess, Managing Director of Vital Transformation, speak on the impacts of the Inflation Reduction Act on the early-stage life science industry.

  • Statement

    Incubate Letter on Reconciliation Drug Pricing Provisions
    07.15.2022

    Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package

  • Statement

    Incubate Statement on Federal Drug Price Provisions
    07.06.2022

    See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.